Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10 mai 2024 14h56 HE
|
Optinose, Inc.
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18 janv. 2024 12h00 HE
|
Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
10 août 2023 07h00 HE
|
Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
04 mai 2023 07h00 HE
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 avr. 2023 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
21 févr. 2023 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
10 nov. 2022 07h00 HE
|
Optinose, Inc.
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps...
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
09 nov. 2022 15h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
07 nov. 2022 15h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
07 mars 2022 07h00 HE
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...